ZIM Laboratories Valuation
Is ZIMLAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Por debajo del valor justo
Muy por debajo del valor justo
Price-To-Earnings vs. similares
Price-To-Earnings vs. Industria
PM vs. Ratio Justo
Pronóstico de los analistas
Share Price vs Fair Value
What is the Fair Price of ZIMLAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Por debajo del valor justo: ZIMLAB (₹113.1) cotiza por encima de nuestra estimación de valor razonable (₹82.72)
Muy por debajo del valor justo: ZIMLAB cotiza por encima de nuestra estimación del valor razonable.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ZIMLAB?
Other financial metrics that can be useful for relative valuation.
What is ZIMLAB's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | ₹4.92b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1.5x |
Enterprise Value/EBITDA | 13.4x |
PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does ZIMLAB's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 42x | ||
524212 Wanbury | 23.4x | n/a | ₹5.5b |
531146 Medicamen Biotech | 45x | n/a | ₹5.7b |
540937 Medico Remedies | 57.1x | n/a | ₹4.0b |
ACCENTMIC Accent Microcell | 42.6x | n/a | ₹5.5b |
ZIMLAB ZIM Laboratories | 30x | n/a | ₹4.9b |
Price-To-Earnings vs. similares: ZIMLAB es un buen valor basado en su Ratio Price-To-Earnings (30.6x) comparado con la media de sus homólogos (37.8x).
Price to Earnings Ratio vs Industry
How does ZIMLAB's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?
Price-To-Earnings vs. Industria: ZIMLAB es un buen valor basado en su Ratio Price-To-Earnings (33.7x) comparado con la media del sector Indian Pharmaceuticals (34.9x).
Price to Earnings Ratio vs Fair Ratio
What is ZIMLAB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 30x |
Fair PE Ratio | n/a |
PM vs. Ratio Justo: Datos insuficientes para calcular ZIMLAB's Price-To-Earnings Fair Ratio para el análisis de valoración.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Pronóstico de los analistas: Datos insuficientes para mostrar el pronóstico de precios.